WallStreetZenWallStreetZen

NYSE: NVO
Novo Nordisk A S Stock Forecast, Predictions & Price Target

Open Broker Account

Should I buy or sell NVO stock?

Based on 5 analysts offering ratings for Novo Nordisk A S.
Hold
Strong Buy
3 analysts 60%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
2 analysts 40%

Be the first to know when Wall Street analysts revise their NVO stock forecasts and price targets.

NVO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
UBS
Top 37%
64
Strong SellDowngradesN/AN/A2022-06-28
JP Morgan
Bottom 44%
44
Strong BuyUpgradesN/AN/A2022-06-07
Guggenheim
Bottom 4%
4
Strong BuyUpgradesN/AN/A2022-05-31
Deutsche Bank
Bottom 32%
32
Strong BuyUpgradesN/AN/A2022-03-16
Liberum
Bottom 50%
50
Strong SellDowngradesN/AN/A2022-01-25

1 of 1

Forecast return on equity

Is NVO forecast to generate an efficient return?
Company
126.05%
Industry
18.02%
Market
121.74%
NVO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVO forecast to generate an efficient return on assets?
Company
42.87%
Industry
13.83%
NVO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVO earnings per share forecast

What is NVO's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.41+9.51%
Avg 2 year Forecast
$4.17+33.91%
Avg 3 year Forecast
$4.85+55.75%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

NVO revenue forecast

What is NVO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$24.5B+11.11%
Avg 2 year Forecast
$28.5B+28.96%
Avg 3 year Forecast
$31.3B+41.5%
NVO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVO earnings growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
17.15%
Industry
8.59%
Market
16.88%
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
NVO's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

NVO revenue growth forecast

How is NVO forecast to perform vs Biotechnology companies and vs the US market?
Company
13.31%
Industry
24.14%
Market
8.59%
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVO$99.63N/AN/AHold
REGN$688.87$751.61+9.11%Buy
VRTX$289.54$294.67+1.77%Buy
MRNA$118.25$239.92+102.89%Buy
BNTX$134.88$237.43+76.03%Buy

Novo Nordisk A S Stock Forecast FAQ

Is Novo Nordisk A S Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: NVO) stock is to Hold NVO stock.

Out of 5 analysts, 3 (60%) are recommending NVO as a Strong Buy, 0 (0%) are recommending NVO as a Buy, 0 (0%) are recommending NVO as a Hold, 0 (0%) are recommending NVO as a Sell, and 2 (40%) are recommending NVO as a Strong Sell.

If you're new to stock investing, here's how to buy Novo Nordisk A S stock.

What is NVO's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: NVO) Novo Nordisk A S's current Earnings Per Share (EPS) is $3.03. On average, analysts forecast that NVO's EPS will be $3.41 for 2022, with the lowest EPS forecast at $3.37, and the highest EPS forecast at $3.48. On average, analysts forecast that NVO's EPS will be $4.17 for 2023, with the lowest EPS forecast at $4.04, and the highest EPS forecast at $4.34. In 2024, NVO's EPS is forecast to hit $4.85 (min: $4.74, max: $4.96).

What is NVO's forecast return on equity (ROE) for 2022-2025?

(NYSE: NVO) forecast ROE is 126.05%, which is considered strong.

What is NVO's earnings growth forecast for 2022-2024?

(NYSE: NVO) Novo Nordisk A S's forecast annual earnings growth rate of 17.15% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.59%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Novo Nordisk A S's earnings in 2022 is $6,904,234,972.On average, 5 Wall Street analysts forecast NVO's earnings for 2022 to be $7,877,100,000, with the lowest NVO earnings forecast at $7,784,700,000, and the highest NVO earnings forecast at $8,038,800,000. On average, 5 Wall Street analysts forecast NVO's earnings for 2023 to be $9,632,700,000, with the lowest NVO earnings forecast at $9,332,400,000, and the highest NVO earnings forecast at $10,025,400,000.

In 2024, NVO is forecast to generate $11,203,500,000 in earnings, with the lowest earnings forecast at $10,949,400,000 and the highest earnings forecast at $11,457,600,000.

What is NVO's revenue growth forecast for 2022-2024?

(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 13.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.14%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Novo Nordisk A S's revenue in 2022 is $21,482,377,049.On average, 3 Wall Street analysts forecast NVO's revenue for 2022 to be $56,685,990,900,000, with the lowest NVO revenue forecast at $56,633,161,200,000, and the highest NVO revenue forecast at $56,765,108,400,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2023 to be $65,790,800,460,000, with the lowest NVO revenue forecast at $64,388,940,000,000, and the highest NVO revenue forecast at $67,488,451,800,000.

In 2024, NVO is forecast to generate $72,188,978,400,000 in revenue, with the lowest revenue forecast at $70,422,336,600,000 and the highest revenue forecast at $74,023,811,400,000.

What is NVO's forecast return on assets (ROA) for 2022-2025?

(NYSE: NVO) forecast ROA is 42.87%, which is higher than the forecast US Biotechnology industry average of 13.83%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.